• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-1 filed by 60 Degrees Pharmaceuticals Inc.

    2/14/25 4:37:51 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SXTP alert in real time by email

    Unavailable

    Get the next $SXTP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SXTP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SXTP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Dow Geoffrey S was granted 4,376 shares, increasing direct ownership by 20% to 26,171 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      6/9/25 5:23:56 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Xu Cheryl bought $14,410 worth of shares (5,000 units at $2.88), increasing direct ownership by 46% to 15,816 units (SEC Form 4)

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      6/5/25 8:53:09 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President and CEO Dow Geoffrey S

      4 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Issuer)

      1/24/25 4:52:30 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SXTP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

      New 8-count bottles now available through major retail pharmaciesARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria WASHINGTON, June 04, 2025 (GLOBE NEWSWIRE) --  60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the introduction of a new 8-count bottle format for ARAKODA® (tafenoquine). The 8-count bottle format may be suitable for use with patients who are making shorter trips to areas of the world where malaria is endemic. The new format expands the packaging options available to he

      6/4/25 8:56:00 AM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

      25,000 U.S. adults per year claim reimbursement for medical costs associated with babesiosis v. CDC estimates of 2,000A full 45 percent of persistent babesiosis cases include chronic fatigueHealthcare providers treating patients who present with unexplained chronic fatigue may wish to consider babesiosis as a differential diagnosisCompany plans to submit a new drug application (NDA) to FDA in 2026, has two babesiosis clinical trials underway with another anticipated to commence enrollment later this year WASHINGTON, June 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new me

      6/3/25 8:49:00 AM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

      Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand.Gross profit increased 124% to $90.3 thousand. WASHINGTON, May 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2025 year, ended March 31, 2025. Financial Highlights for the Quarter Ended March 31, 2025: Net product revenues increased approximately 55% from $105.7 thousand for the first quarter of 2024 to approximately $163.6 thousand for the first quarter of 2025; the Company credits growth from domes

      5/15/25 4:31:00 PM ET
      $SXTP
      Biotechnology: Pharmaceutical Preparations
      Health Care